In an analysis of more than half a million men with hypogonadism, testosterone replacement therapy is tied to a 16% lower ...

This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment ...

This article was reviewed by Knox Beasley, MD Oral vs. Topical Minoxidil: Which Is Better for Hair Loss? Minoxidil is one of ...

The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.

The FDA has approved Bondlido (lidocaine topical system 10%) for the relief of pain associated with postherpetic neuralgia in adults.